Assesses women who were screened for cervical cancer using any of the following criteria:
- Women 21–64 years of age who had cervical cytology performed within the last 3 years.
- Women 30–64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Women 30–64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last 5 years.
THE Bottom Line
Cervical cancer is a disease in which cells in the cervix (the lower, narrow end of the uterus) grow out of control. Cervical cancer was one of the most common causes of cancer death for American women; effective screening and early detection of cervical pre-cancers have led to a significant reduction in this death rate.1
Results – National Averages
Cervical Cancer Screening Rate*
|Measure Year||Commercial HMO||Commercial PPO||Medicaid HMO|
*This measure has existed since 1999 and was updated in 2013 to reflect new guidelines from the US Preventive Services Task Force
This State of Healthcare Quality Report classifies health plans differently than NCQA’s Quality Compass. HMO corresponds to All LOBs (excluding PPO and EPO) within Quality Compass. PPO corresponds to PPO and EPO within Quality Compass.
Figures do not account for changes in the underlying measure that could break trending. Contact Information Products via my.ncqa.org for analysis that accounts for trend breaks.
- American Cancer Society. 2020. “Key Statistics for Cervical Cancer.”
https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html Last modified July 30.